Headlands Technologies LLC Raises Position in Insmed, Inc. $INSM

Headlands Technologies LLC grew its stake in Insmed, Inc. (NASDAQ:INSM) by 1,355.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,855 shares of the biopharmaceutical company’s stock after purchasing an additional 38,047 shares during the quarter. Headlands Technologies LLC’s holdings in Insmed were worth $4,356,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Reflection Asset Management bought a new stake in shares of Insmed in the 4th quarter worth $30,000. CIBC Private Wealth Group LLC lifted its position in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. Raiffeisen Bank International AG bought a new stake in Insmed in the 4th quarter worth about $32,000. Larson Financial Group LLC lifted its position in shares of Insmed by 137.0% during the 4th quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 148 shares in the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new position in shares of Insmed in the 4th quarter worth approximately $49,000.

Insmed Stock Performance

Shares of INSM opened at $118.54 on Monday. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The stock’s fifty day moving average price is $113.64 and its two-hundred day moving average price is $125.88. The firm has a market cap of $25.89 billion, a PE ratio of -28.84 and a beta of 0.81.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same quarter in the prior year, the company earned ($1.70) EPS. The firm’s quarterly revenue was up 296.1% compared to the same quarter last year. On average, equities research analysts forecast that Insmed, Inc. will post -1.83 EPS for the current year.

Insider Buying and Selling at Insmed

In other news, insider Michael Alexander Smith sold 2,159 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $220,800.93. Following the sale, the insider owned 39,454 shares of the company’s stock, valued at $4,034,960.58. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 21,398 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the sale, the chief executive officer owned 258,917 shares in the company, valued at $26,751,304.44. The trade was a 7.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 288,291 shares of company stock worth $37,091,566 over the last three months. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on INSM shares. Morgan Stanley reiterated an “overweight” rating and set a $218.00 price target on shares of Insmed in a report on Friday, August 7th. Royal Bank Of Canada decreased their target price on Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Truist Financial reiterated a “buy” rating and set a $195.00 target price (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. Wells Fargo & Company boosted their price target on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Mizuho set a $192.00 price target on shares of Insmed in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $205.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.